HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Nakaraang pagsara
$2.47
Sakop ng araw
$2.31 - $2.53
Sakop ng taon
$1.87 - $4.20
Market cap
21.81M USD
Average na Volume
11.54K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.00M | — |
Gastos sa pagpapatakbo | 5.95M | -1.26% |
Net na kita | -4.61M | 14.07% |
Net profit margin | -461.00 | — |
Kita sa bawat share | -0.55 | 16.67% |
EBITDA | -4.91M | 17.90% |
Aktuwal na % ng binabayarang buwis | 0.00% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 31.24M | -38.17% |
Kabuuang asset | 35.00M | -36.00% |
Kabuuang sagutin | 5.68M | -16.40% |
Kabuuang equity | 29.32M | — |
Natitirang share | 27.70M | — |
Presyo para makapag-book | 0.70 | — |
Return on assets | -33.80% | — |
Return on capital | -39.23% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -4.61M | 14.07% |
Cash mula sa mga operasyon | -4.53M | -11.28% |
Cash mula sa pag-invest | 1.39M | 124.31% |
Cash mula sa financing | -96.00K | -500.00% |
Net change in cash | -3.30M | 66.45% |
Malayang cash flow | -2.95M | -25.90% |
Tungkol
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Itinatag
1980
Headquarters
Website
Mga Empleyado
26
